netarsudil netarsudil netarsudil, sold under the brand name rhopressa among others, is a medication for the treatment of glaucoma. in the united states, in december 2017, the food and drug administration (fda) approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension. the european medicines agency approved it in 2019 for the same uses under the brand name rhokiinsa. netarsudilclinical datapronunciationne tar soo dil trade namesrhopressa, rhokiinsaother namesar-13324ahfs/drugs.commonographmedlineplusa618014license data eu ema: by inn us dailymed: netarsudil routes ofadministrationeye drops, topicalatc codes01ex05 (who) legal statuslegal status us: ℞-only eu: rx-only pharmacokinetic datametabolismesterases in the corneametabolitesar-13503 (active metabolite)elimination half-life16–17 hrsduration of action≥ 24 hrsidentifiers iupac name phenyl]methyl 2,4-dimethylbenzoate cas number1254032-66-0pubchem cid66599893drugbankdb13931chemspider34980598uniiw6i5qdt7qikeggd11030as salt: d11031echa infocard100.251.524 chemical and physical dataformulac28h27n3o3molar mass453.542 g·mol−13d model (jsmol)interactive image smiles cc1ccc(c(c1)c)c(=o)occ2ccc(cc2)(cn)c(=o)nc3ccc4cnccc4c3 inchi inchi=1s/c28h27n3o3/c1-18-3-10-25(19(2)13-18)28(33)34-17-20-4-6-21(7-5-20)26(15-29)27(32)31-24-9-8-23-16-30-12-11-22(23)14-24/h3-14,16,26h,15,17,29h2,1-2h3,(h,31,32)/t26-/m1/s1key:ourrxqugyqrvml-aremukbssa-n the fda considers it to be a first-in-class medication. contraindications netarsudil has no contraindications apart from known hypersensitivity to the drug. adverse effects the most common side effects are hyperaemia (increased blood flow associated with redness, in 51% of patients) in the conjunctiva, cornea verticillata (drug deposits in the cornea, in 17%), and eye pain (in 17%). all other side effects occur in fewer than 10% of people. hypersensitivity reactions occur in fewer than 1%. overdose overdosing netarsudil is unlikely because concentrations in the body are so low that they are generally not detectable. interactions no interaction studies have been done. the european label recommends to apply other eye drops at least five minutes before, and eye ointments at least five minutes after netarsudil drops. pharmacology mechanism of action this drug's mechanism of action is not entirely clear. it inhibits the enzyme rho kinase. this appears to increase outflow of aqueous humor through the trabecular meshwork, and also to reduce pressure in the veins of the episcleral layer. the drug also inhibits the norepinephrine transporter. pharmacokinetics after instillation into the eye, netarsudil is cleaved by esterases in the cornea to ar-13503, which is the active metabolite. concentrations reached in the blood plasma are so low that they are generally not detectable. to judge from animal models, the drug acts for at least 24 hours. its elimination half-life is 16 to 17 hours (in rabbits). ar-13503, the active metabolite chemistry the drug is used in form of a salt, netarsudil dimesilate, which is a white to light yellow crystalline powder. it is a weak acid and moderately hygroscopic, freely soluble in water and soluble in methanol.